Document is current
Any future updates will be listed below
-
Authors
Skafte, Ann https://orcid.org/0009-0006-1024-2224
Vidal-Calvo, Elena Ethel https://orcid.org/0000-0001-9655-2106
Choudhary, Swati
Mujollari, Joana
Dagil, Robert https://orcid.org/0000-0002-5594-0716
Martin-Salazar, Anne
Oo, Htoo Zarni https://orcid.org/0009-0009-8514-2713
Duvnjak, Lara https://orcid.org/0009-0005-4540-3764
Theander, Thor G.
Daugaard, Mads
Gustavsson, Tobias https://orcid.org/0000-0003-0243-2248
Salanti, Ali https://orcid.org/0000-0003-2207-5575
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden (NNF22OC0076055)
Novo Nordisk Fonden (NNF23SA0087869)
Novo Nordisk Fonden (NNF23OC0086106)
Terry Fox Research Institute (1109)
- License Information
-
More Information
Article History
Received: 14 May 2025
Revised: 11 December 2025
Accepted: 21 January 2026
First Online: 24 January 2026
Competing interests
: ASa, MD, and TGT are shareholders of VAR2 Pharmaceuticals. The antibodies are subject to a patenting process owned by VAR2 Pharmaceuticals. The remaining authors declare no competing interests.
